Anthos doubles down on its novel blood thinner

The Novartis spin-off Anthos has long looked like the odd company out in the race to get a factor XI inhibitor, a novel class of anticoagulant, to market. The group, which is backed by the private equity firm Blackstone, is surrounded by big pharma hitters like Bayer, Bristol Myers Squibb and Johnson & Johnson.